Neisseria gonorrhoeae infections is a sexually transmitted disease that is caused by Neisseria gonorrhoeae bacterium which cause infections in throat, rectum, and genitals. In men, the observed symptoms of gonorrhoeae infections are burning sensation during urination, painful and swollen testicles, and white, green or yellow discharge from the penis. In women, the observed symptoms of gonorrhoeae are vaginal bleeding during periods, increased vaginal discharged, and burning sensation during urination. The unprotected vaginal, oral or anal sex are the risk factors for gonorrhoeae infections. Entasis Therapeutics, Inc. is in the process of developing ETX0914 as a bacterial type II topoisomerases inhibitor, for the treatment of gonorrhoeae infections. Therapyx, Inc. is also in the process of developing IL12 NanoCap for the treatment of gonorrhoeae infection. Some of the companies having the pipeline of neisseria gonorrhoeae infections include Therapyx, Inc., Entasis Therapeutics, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.